Monday, December 05, 2016 12:30:01 PM
Is level of passion on both sides. The rate of posting re NNVC relative to the capsize of the company is truly amazing. That this little company creates as much controversy and conversation as it does is truly Trump-like.
Visit the board of VRX, a far larger enterprise that has been written up extensively in the financial press, in large part due to hugely the mistaken stake taken by hedge fund manager Bill Ackerman. You will not see the number of post we get here or level of passion.
BTW Ackerman finally acknowledged that his bet on VRX was a mistake but he only did so after riding the stock down from over $260 to now 15.125. All the way down he rationalized his position. A text-book case of confirmation bias. I think the only thing that dislodged him from that mental trap was the sheer embarrassment of trying to make the bullish case in the face of such a huge price decline.
I don't know about anyone else by I find the crowd psychological dynamics fascinating. If Gene could only bottle his passion spray, NNVC would really have something.
I have it on decent authority that two of the brokerage firms that have been offering to loan NNVC stock for short sales will cease doing so as of January 1. I don't know what to make of that other than lack of demand.
Trendliner
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City • GlobeNewswire Inc. • 05/04/2023 10:45:00 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM